You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
Financial news, mergers and acquisitions, partnerships, and alliances.
The firm reissued its full-year guidance and said it expects to sell 60 instruments in the US for the remainder of the year.
The immune sequencing firm also provided an update on the development of its ImmunoSeq Dx clinical product for detecting prior infection with SARS-CoV-2.
The skin cancer diagnostics company said it delivered 19 percent fewer DecisionDx-Melanoma test results in Q2 2020 than in the previous year's second quarter.
HTG will work directly with biopharma customers to build companion diagnostic development programs, with potential tests developed using either a Thermo Fisher Scientific or Illumina platform.
The three tests are designed to detect antibodies, including immunoglobulin G and M, against SARS-CoV-2 in human serum and plasma.